ATE331514T1 - Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase - Google Patents

Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase

Info

Publication number
ATE331514T1
ATE331514T1 AT00991704T AT00991704T ATE331514T1 AT E331514 T1 ATE331514 T1 AT E331514T1 AT 00991704 T AT00991704 T AT 00991704T AT 00991704 T AT00991704 T AT 00991704T AT E331514 T1 ATE331514 T1 AT E331514T1
Authority
AT
Austria
Prior art keywords
altering
protein kinase
tyrosine protein
kit tyrosine
indolinone derivatives
Prior art date
Application number
AT00991704T
Other languages
English (en)
Inventor
Ken Lipson
Gerald Mcmahon
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22624773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE331514(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sugen Inc filed Critical Sugen Inc
Application granted granted Critical
Publication of ATE331514T1 publication Critical patent/ATE331514T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00991704T 1999-12-22 2000-12-22 Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase ATE331514T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17169399P 1999-12-22 1999-12-22

Publications (1)

Publication Number Publication Date
ATE331514T1 true ATE331514T1 (de) 2006-07-15

Family

ID=22624773

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00991704T ATE331514T1 (de) 1999-12-22 2000-12-22 Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase

Country Status (14)

Country Link
US (3) US20020010203A1 (de)
EP (1) EP1255536B1 (de)
JP (1) JP5004392B2 (de)
AT (1) ATE331514T1 (de)
AU (1) AU784266B2 (de)
CA (1) CA2395461C (de)
CY (1) CY1106165T1 (de)
DE (1) DE60029138T2 (de)
DK (1) DK1255536T3 (de)
ES (1) ES2267605T3 (de)
MX (1) MXPA02006263A (de)
NZ (1) NZ519697A (de)
PT (1) PT1255536E (de)
WO (1) WO2001045689A2 (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048629B2 (en) * 1996-03-15 2011-11-01 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
CA2248981C (en) 1996-03-15 2009-11-24 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays
CZ303705B6 (cs) * 2000-02-15 2013-03-27 Sugen, Inc. Pyrrolem substituovaná 2-indolinonová sloucenina pro pouzití jako inhibitor proteinkináz a farmaceutická kompozice s jejím obsahem
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
WO2003004007A2 (en) * 2001-06-29 2003-01-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd)
US7741335B2 (en) 2001-06-29 2010-06-22 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
JP2005502614A (ja) * 2001-06-29 2005-01-27 アブ サイエンス 多発性硬化症（ｍｓ）を治療するためのチロシンキナーゼ阻害剤の使用方法
US7700610B2 (en) * 2001-06-29 2010-04-20 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
WO2003002109A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
WO2003002114A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
US20040266797A1 (en) * 2001-06-29 2004-12-30 Alain Moussy Use of potent,selective and non toxic c-kit inhibitors for treating tumor angiogensis
WO2003002105A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating bone loss
DE60223063T2 (de) 2001-06-29 2008-07-17 Ab Science C-kit inhibitoren
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US7419777B2 (en) * 2001-08-21 2008-09-02 Ventana Medical Systems, Inc. Method and quantification assay for determining c-kit/SCF/pAKT status
ATE401078T1 (de) * 2001-09-20 2008-08-15 Ab Science Die verwendung von c-kithemmern zur förderung des haarwuchses
DE60228278D1 (de) * 2001-09-20 2008-09-25 Ab Science Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
ATE388711T1 (de) * 2001-09-20 2008-03-15 Ab Science C-kithemmer zur behandlung von bakteriellen infektionen
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
WO2003037328A1 (en) * 2001-10-30 2003-05-08 Applied Research Systems Ars Holding N.V. Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
US7119209B2 (en) 2002-02-15 2006-10-10 Pharmacia & Upjohn Company Process for preparing indolinone derivatives
EP1478380B1 (de) * 2002-02-27 2006-08-02 AB Science Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
EP1347041A1 (de) * 2002-03-21 2003-09-24 Universitätsklinikum Benjamin Franklin der Freien Universität Berlin Permanente von Wachstumsfaktoren unabhängige Zelllinie und eine Methode zur Herstellung
US20050032871A1 (en) * 2002-09-03 2005-02-10 Sugen, Inc. Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
AR042042A1 (es) * 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
JPWO2004080462A1 (ja) * 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
CN100450998C (zh) 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ｒｅｔ調節剤の開発のための化合物および方法
WO2006001954A2 (en) * 2004-05-20 2006-01-05 Puget Sound Blood Center And Program Methods for promoting the formation of platelets and for treating blood and bone marrow disorders
US7498342B2 (en) * 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
WO2006009797A1 (en) * 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
EP1797881B1 (de) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
US7846941B2 (en) 2005-05-17 2010-12-07 Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor
NZ565255A (en) * 2005-06-22 2010-04-30 Plexxikon Inc Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
EP1925941B1 (de) * 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Verfahren zur vorhersage der wirksamkeit eines vaskularisierungsinhibitors
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
KR100990590B1 (ko) * 2005-09-01 2010-10-29 에자이 알앤드디 매니지먼트 가부시키가이샤 붕해성이 개선된 의약 조성물의 제조 방법
DE602006008015D1 (de) 2005-09-19 2009-09-03 Pfizer Prod Inc Feste salzformen eines pyrrolsubstituierten 2-indolinons
ES2775049T3 (es) 2005-10-21 2020-07-23 Univ California Mutaciones del gen SHP-2 en melanomas
AU2006309551B2 (en) * 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
WO2007061127A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
WO2008001956A1 (en) * 2006-06-29 2008-01-03 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
AU2007275683B2 (en) 2006-07-20 2012-05-10 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
AU2007275682B2 (en) 2006-07-20 2012-05-17 Amgen Inc. Substituted pyridone compounds and methods of use
US8048411B2 (en) * 2006-08-17 2011-11-01 The Cleveland Clinic Foundation Co-transplantation of hepatic stellate cells and islet cells
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
AU2007296740B2 (en) * 2006-09-11 2012-09-27 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7872018B2 (en) 2006-12-21 2011-01-18 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
US8962655B2 (en) * 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
WO2008138184A1 (fr) * 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
EP2068152A1 (de) 2007-12-06 2009-06-10 Max-Delbrück-Centrum für Molekulare Medizin (MDC) c-Kit als neuartiges Target zur Schmerzbehandlung
WO2009096377A1 (ja) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. 血管阻害物質とタキサンとの併用
EP2113248A1 (de) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmazeutische Zusammensetzung mit N-[2-(Diethylamino)ethyl]-5-[(5-Fluor-1,2-dihydro-2-oxo-3H-Indol-3-yliden)methyl]-2-,4Dimethyl-1H-Pyrrol-3-Carboxamid
EP2090306A1 (de) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmazeutische Zusammensetzungen mit N-[2-(Diethylamino)ethyl]-5-[5-fluor-1,2-dihydro-2-oxo-3H-indol-3-yliden)methyl]-2,4-dimethyl-1H-pyrrol-3-carboxamid
EP2098521A1 (de) 2008-03-06 2009-09-09 Ratiopharm GmbH Kristalline Formen von N-[2-(diethylamino)-Ethyl]-5-[Fluor-1,2-dihydro-2-oxo-3H-Indol-3-yliden)methyl]-2,4-Dimethyl-1H-Pyroll-3-Carboxamid und Verfahren zu ihrer Herstellung
EP2138167A1 (de) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmazeutische Zusammensetzung mit N-[2-(Diethylamino)ethyl]-5-[(5-Fluor-1,2-dihydro-2-oxo-3H-Indol-3-yliden)methyl]-2,4-Dimethyl-1H-Pyrrol-3-Carboxamid
US8993615B2 (en) 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
WO2010098888A1 (en) * 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
PL2414356T3 (pl) 2009-04-03 2016-02-29 Hoffmann La Roche Kompozycje {3-[5-(4-chlorofenylo)-1H-pirolo[2,3-b]pirydyno-3-karbonylo]-2,4-difluorofenylo}-amidu kwasu propano-1-sulfonowego i ich zastosowania
CN101885698B (zh) * 2009-05-15 2012-07-11 浙江海正药业股份有限公司 一种吡咯基丙烯酰胺类化合物及其在舒尼替尼合成中的应用
EP2255792A1 (de) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmazeutische Zusammensetzungen für N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-Dimenthyl-1H-Pyrrol-3-Carboxamid
EP2264027A1 (de) 2009-05-27 2010-12-22 Ratiopharm GmbH Verfahren zur Herstellung von N-[2-(Diethylamino)ethyl]-5-[(5-Fluor-1,2-dihydro-2-oxo-3H-Indol-3-yliden)methyl]-2,4-Dimethyl-1H-Pyrrol-3-Carboxamid
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
ME02359B (de) 2009-08-19 2016-06-20 Eisai R&D Man Co Ltd Chinolinderivathaltige pharmazeutische zusammensetzung
PE20121327A1 (es) 2009-11-06 2012-10-18 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello
US20120289571A1 (en) * 2009-12-31 2012-11-15 Enzon Pharmaceuticals, Inc. Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2011119777A2 (en) 2010-03-23 2011-09-29 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
RU2560683C2 (ru) 2010-06-25 2015-08-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
US20120076797A1 (en) * 2010-07-14 2012-03-29 Butte Atul J Modulation of kit signaling and hematopoietic cell development by IL-4 receptor modulation
WO2012027716A1 (en) 2010-08-27 2012-03-01 Collabrx, Inc. Method to treat melanoma in braf inhibitor-resistant subjects
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
JP2014503500A (ja) 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9827326B2 (en) 2010-12-23 2017-11-28 Nektar Therapeutics Polymer-sunitinib conjugates
JP6009457B2 (ja) 2010-12-23 2016-10-19 ネクター セラピューティクス ポリマー−デスエチルスニチニブコンジュゲート
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
PT2672967T (pt) 2011-02-07 2018-12-07 Plexxikon Inc Compostos e métodos de modulação da quinase e suas indicações
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
US8630703B2 (en) 2011-03-09 2014-01-14 Technion Research & Development Foundation Limited Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination
EP2700403B1 (de) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutikum für tumor
ES2841809T3 (es) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP3381943B1 (de) 2012-07-25 2022-03-16 Celldex Therapeutics, Inc. Anti-kit-antikörper und verwendungen davon
AU2013312477B2 (en) 2012-09-06 2018-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2895170A4 (de) * 2012-09-14 2016-07-20 Childrens Medical Center Hemmung von viralem infektionsausgelöstem asthma mit einem c-kit-hemmer
EP2935248B1 (de) 2012-12-21 2018-02-28 Plexxikon Inc. Verbindungen und verfahren zur kinasemodulation und anzeigen dafür
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
EP2968113B8 (de) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systeme zur verzögerten intraokularen abgabe schwerlöslicher verbindungen aus einem implantat mit einem portabgabesystem
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
US10450295B2 (en) * 2013-08-09 2019-10-22 Acclaim BioMed USA LLC Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis
ES2813877T3 (es) 2013-08-28 2021-03-25 Crown Bioscience Inc Taicang Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN113975386A (zh) * 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
JO3783B1 (ar) 2014-08-28 2021-01-31 Eisai R&D Man Co Ltd مشتق كوينولين عالي النقاء وطريقة لإنتاجه
JP6792546B2 (ja) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
CA2978226C (en) 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
WO2016184793A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
JP6757959B2 (ja) 2015-06-16 2020-09-23 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ 抗がん剤
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
EA037327B1 (ru) 2015-09-22 2021-03-12 Грейбуг Вижн, Инк. Соединения и композиции для лечения глазных расстройств
ES2971448T3 (es) 2017-02-08 2024-06-05 Eisai R&D Man Co Ltd Composición farmacéutica para el tratamiento de tumores
EP3600324A4 (de) 2017-03-23 2020-12-09 Graybug Vision, Inc. Arzneimittel und zusammensetzungen zur behandlung von augenkrankheiten
US11160870B2 (en) 2017-05-10 2021-11-02 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
MX2019013014A (es) 2017-05-16 2020-08-06 Eisai R&D Man Co Ltd Tratamiento de carcinoma hepatocelular.
BR112022021920A2 (pt) 2020-04-29 2023-01-17 Plexxikon Inc Síntese de compostos heterocíclicos
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
WO1991015495A1 (en) 1990-04-02 1991-10-17 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
JPH06503095A (ja) 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
CZ291047B6 (cs) 1992-10-28 2002-12-11 Genentech, Inc. Farmaceutický prostředek obsahující antagonisty faktoru růstu vaskulárních endoteliálních buněk
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9611797D0 (en) * 1996-06-06 1996-08-07 Pharmacia Spa Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors
WO1998007695A1 (en) * 1996-08-23 1998-02-26 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
WO1998045708A1 (en) * 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
EP0984930B1 (de) * 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinonderivate als modulatoren der proteinkinase-ativität
DE69819003T2 (de) 1997-08-02 2004-07-15 The Procter & Gamble Company, Cincinnati Verfahren zur herstellung von ether-verkappten poly(oxyalkyl)alkoholtensiden
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
AU3363599A (en) * 1998-03-26 1999-10-18 Max-Planck Institut Fur Biochemie Heterocyclic families of compounds for the modulation of tyrosine protein kinase
US6514981B1 (en) 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
WO1999061422A1 (en) * 1998-05-29 1999-12-02 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
PT1157019E (pt) * 1998-12-17 2003-06-30 Hoffmann La Roche 4-alcenil (e alcinil) oxindolos como inibidores dequinases dependentes de ciclina em particular cdk2
US6689806B1 (en) * 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
AU3770000A (en) * 1999-03-24 2000-10-09 Sugen, Inc. Indolinone compounds as kinase inhibitors
US6878733B1 (en) * 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
PT1233943E (pt) * 1999-11-24 2011-09-01 Sugen Inc Formulações para agentes farmacêuticos ionizáveis como ácidos livres ou bases livres
US6339100B1 (en) * 1999-12-29 2002-01-15 The Trustees Of Columbia University In The City Of New York Methods for inhibiting mastocytosis

Also Published As

Publication number Publication date
NZ519697A (en) 2004-08-27
EP1255536B1 (de) 2006-06-28
US20050288353A1 (en) 2005-12-29
CA2395461C (en) 2010-05-25
DE60029138T2 (de) 2007-06-06
US20040002534A1 (en) 2004-01-01
CA2395461A1 (en) 2001-06-28
EP1255536A2 (de) 2002-11-13
WO2001045689A3 (en) 2002-01-03
WO2001045689A2 (en) 2001-06-28
MXPA02006263A (es) 2004-02-26
HK1050642A1 (en) 2003-07-04
JP5004392B2 (ja) 2012-08-22
US20020010203A1 (en) 2002-01-24
AU784266B2 (en) 2006-03-02
US7211600B2 (en) 2007-05-01
AU3436301A (en) 2001-07-03
PT1255536E (pt) 2006-09-29
JP2004500363A (ja) 2004-01-08
ES2267605T3 (es) 2007-03-16
DK1255536T3 (da) 2006-10-30
DE60029138D1 (de) 2006-08-10
CY1106165T1 (el) 2011-06-08

Similar Documents

Publication Publication Date Title
ATE331514T1 (de) Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase
ATE292623T1 (de) 2-indolinonderivate als modulatoren der proteinkinase-ativität
WO1995024190A3 (en) Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
ATE437867T1 (de) Substituierte indole zur modulierung von nfkb- aktivität
EP2609919A3 (de) c-Met-Modulatoren und Verwendungsverfahren
EA200870048A1 (ru) ГЕТЕРОАРИЛ-ЗЕМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
WO2004006846A3 (en) Receptor-type kinase modulators and methods of use
HRP20050059B1 (hr) Novi inhibitori kinaza
UA98297C2 (en) Triazolopyridazines as tyrosine kinase modulators
DE60206636D1 (de) THERAPEUTISCHE 1H-PYRIDO[4,3-b]INDOLE
MXPA02008021A (es) Indolinonas sustituidas con pirroles inhibidoras de proteinquinasas.
EA200200473A1 (ru) Ингибиторы тирозинкиназы
HRP20020748A2 (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
NZ516292A (en) Pyrrolotriazine inhibitors of kinases
MY128449A (en) Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
ATE275400T1 (de) Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
TW200716598A (en) Aminoquinoline and aminoquinazoline kinase modulators
TW200716118A (en) Aminopyrimidines as kinase modulators
MXPA02010759A (es) Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1255536

Country of ref document: EP

REN Ceased due to non-payment of the annual fee